20th Jun 2018 11:48
LONDON (Alliance News) - Deltex Medical Group PLC on Wednesday said it plans to launch new Oesophageal Doppler monitoring technology for high risk patients in US.
In his annual general meeting statement, Deltex Medical Chairman Nigel Keen said the medical technology company has launched TrueVue monitoring platform in the UK, which includes three monitoring options: doppler ultrasound, impedance and arterial waveform analysis.
In the US, the company awaits for regulatory approval to launch the full suite of TrueVue products, Keen said. The TrueVue platform enables clinicians to match the appropriate technology to the risk profile of the patients as they move through the hospital.
The TrueVue platform also enables Deltex to sell its monitoring technologies into a larger addressable market. In the past, the company only sold its products to anaesthetists. It now expanded its operating areas to accident & emergency, awake-surgery and obstetrics areas.
Keen said, in the second half of the year, Deltex intends to work on optimising its sales and marketing activities in order to maximise revenues and addressable markets.
On the operational basis, Deltex will focus on expanding its addressable market and expects to move towards cash generation after maximising sales of monitoring technology, Keen added.
Deltex shares were trading 5.4% lower on Wednesday at 1.23 pence per share.
Related Shares:
Deltex Medical